Education
About Us
Working with TipRanks
Follow Us
OncoZenge AB (DE:8LY)
:8LY
8LY Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.27 - €0.99
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.09M
Enterprise Value€81.75M
Total Cash (Recent Filing)€1.29M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding11,713,244
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)8.31
Price to Sales (P/S)0.00
P/FCF Ratio-9.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
8LY FAQ
What was OncoZenge AB’s price range in the past 12 months?
OncoZenge AB lowest stock price was €0.27 and its highest was €0.99 in the past 12 months.
What is OncoZenge AB’s market cap?
OncoZenge AB’s market cap is €7.09M.
When is OncoZenge AB’s upcoming earnings report date?
OncoZenge AB’s upcoming earnings report date is May 20, 2025 which is 62 days ago.
How were OncoZenge AB’s earnings last quarter?
Currently, no data Available
Is OncoZenge AB overvalued?
According to Wall Street analysts OncoZenge AB’s price is currently Overvalued.
Does OncoZenge AB pay dividends?
OncoZenge AB does not currently pay dividends.
What is OncoZenge AB’s EPS estimate?
OncoZenge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoZenge AB have?
OncoZenge AB has 11,713,244 shares outstanding.
What happened to OncoZenge AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of OncoZenge AB?
Currently, no hedge funds are holding shares in DE:8LY
Company Description
OncoZenge AB
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).
Technical Analysis
Biosergen AB
―
Modus Therapeutics Holding AB
―
Spago Nanomedical AB
―
CombiGene AB
―
Sprint Bioscience AB
―